The Experts below are selected from a list of 24489 Experts worldwide ranked by ideXlab platform
Margaret C. Frame - One of the best experts on this subject based on the ideXlab platform.
-
Src and Focal Adhesion Kinase as therapeutic targets in cancer.
Current opinion in pharmacology, 2008Co-Authors: Valerie G. Brunton, Margaret C. FrameAbstract:Over the past few years small molecule inhibitors of both Src family Kinases and Focal Adhesion Kinase (FAK) have entered clinical studies for the treatment of solid tumours. These Adhesion-linked Kinases are involved in a number of pathways that have impact on the behaviour of tumour cells and the challenge is now, how to take these forward in the clinical setting.
-
the role of Focal Adhesion Kinase in cancer a new therapeutic opportunity
Nature Reviews Cancer, 2005Co-Authors: Gordon W Mclean, Valerie G. Brunton, Neil O Carragher, Egle Avizienyte, Jeff Evans, Margaret C. FrameAbstract:Focal-Adhesion Kinase (FAK) is an important mediator of growth-factor signalling, cell proliferation, cell survival and cell migration. Given that the development of malignancy is often associated with perturbations in these processes, it is not surprising that FAK activity is altered in cancer cells. Mouse models have shown that FAK is involved in tumour formation and progression, and other studies showing that FAK expression is increased in human tumours make FAK a potentially important new therapeutic target.
-
The role of Focal-Adhesion Kinase in cancer — a new therapeutic opportunity
Nature reviews. Cancer, 2005Co-Authors: Gordon W Mclean, Valerie G. Brunton, Neil O Carragher, Egle Avizienyte, Jeff Evans, Margaret C. FrameAbstract:Focal-Adhesion Kinase (FAK) is an important mediator of growth-factor signalling, cell proliferation, cell survival and cell migration. Given that the development of malignancy is often associated with perturbations in these processes, it is not surprising that FAK activity is altered in cancer cells. Mouse models have shown that FAK is involved in tumour formation and progression, and other studies showing that FAK expression is increased in human tumours make FAK a potentially important new therapeutic target.
-
Focal Adhesion Kinase as a potential target in oncology.
Expert opinion on pharmacotherapy, 2003Co-Authors: Gordon W Mclean, Egle Avizienyte, Margaret C. FrameAbstract:Focal Adhesion Kinase (FAK) is a non-receptor tyrosine Kinase that plays a pivotal role in signal transduction at integrin-linked cellular Adhesions, which mediate cell contact with the extracellular matrix. It has been shown to play a role in the survival of anchorage-dependent cells and to be essential for integrin-linked cell migration – processes that are likely to play important roles in the development of malignancies. FAK is upregulated in a wide variety of human epithelial cancers, with expression being closely correlated to invasive potential. Recently, evidence has emerged directly linking FAK expression to tumour development in vivo, raising the possibility that intervention strategies to block FAK function may potentially provide an opportunity for the development of anticancer therapeutics.
Gordon W Mclean - One of the best experts on this subject based on the ideXlab platform.
-
the role of Focal Adhesion Kinase in cancer a new therapeutic opportunity
Nature Reviews Cancer, 2005Co-Authors: Gordon W Mclean, Valerie G. Brunton, Neil O Carragher, Egle Avizienyte, Jeff Evans, Margaret C. FrameAbstract:Focal-Adhesion Kinase (FAK) is an important mediator of growth-factor signalling, cell proliferation, cell survival and cell migration. Given that the development of malignancy is often associated with perturbations in these processes, it is not surprising that FAK activity is altered in cancer cells. Mouse models have shown that FAK is involved in tumour formation and progression, and other studies showing that FAK expression is increased in human tumours make FAK a potentially important new therapeutic target.
-
The role of Focal-Adhesion Kinase in cancer — a new therapeutic opportunity
Nature reviews. Cancer, 2005Co-Authors: Gordon W Mclean, Valerie G. Brunton, Neil O Carragher, Egle Avizienyte, Jeff Evans, Margaret C. FrameAbstract:Focal-Adhesion Kinase (FAK) is an important mediator of growth-factor signalling, cell proliferation, cell survival and cell migration. Given that the development of malignancy is often associated with perturbations in these processes, it is not surprising that FAK activity is altered in cancer cells. Mouse models have shown that FAK is involved in tumour formation and progression, and other studies showing that FAK expression is increased in human tumours make FAK a potentially important new therapeutic target.
-
Focal Adhesion Kinase as a potential target in oncology.
Expert opinion on pharmacotherapy, 2003Co-Authors: Gordon W Mclean, Egle Avizienyte, Margaret C. FrameAbstract:Focal Adhesion Kinase (FAK) is a non-receptor tyrosine Kinase that plays a pivotal role in signal transduction at integrin-linked cellular Adhesions, which mediate cell contact with the extracellular matrix. It has been shown to play a role in the survival of anchorage-dependent cells and to be essential for integrin-linked cell migration – processes that are likely to play important roles in the development of malignancies. FAK is upregulated in a wide variety of human epithelial cancers, with expression being closely correlated to invasive potential. Recently, evidence has emerged directly linking FAK expression to tumour development in vivo, raising the possibility that intervention strategies to block FAK function may potentially provide an opportunity for the development of anticancer therapeutics.
Susan J. Gunst - One of the best experts on this subject based on the ideXlab platform.
-
Depletion of Focal Adhesion Kinase by antisense depresses contractile activation of smooth muscle
American journal of physiology. Cell physiology, 2001Co-Authors: Dale D. Tang, Susan J. GunstAbstract:Focal Adhesion Kinase (FAK) undergoes tyrosine phosphorylation in response to the contractile stimulation of tracheal smooth muscle. We hypothesized that FAK may play an important role in signaling...
-
Mechanosensitive tyrosine phosphorylation of paxillin and Focal Adhesion Kinase in tracheal smooth muscle
The American journal of physiology, 1999Co-Authors: Dachun Tang, Dolly Mehta, Susan J. GunstAbstract:We investigated the role of the integrin-associated proteins Focal Adhesion Kinase (FAK) and paxillin as mediators of mechanosensitive signal transduction in tracheal smooth muscle. In muscle strip...
Valerie G. Brunton - One of the best experts on this subject based on the ideXlab platform.
-
Src and Focal Adhesion Kinase as therapeutic targets in cancer.
Current opinion in pharmacology, 2008Co-Authors: Valerie G. Brunton, Margaret C. FrameAbstract:Over the past few years small molecule inhibitors of both Src family Kinases and Focal Adhesion Kinase (FAK) have entered clinical studies for the treatment of solid tumours. These Adhesion-linked Kinases are involved in a number of pathways that have impact on the behaviour of tumour cells and the challenge is now, how to take these forward in the clinical setting.
-
the role of Focal Adhesion Kinase in cancer a new therapeutic opportunity
Nature Reviews Cancer, 2005Co-Authors: Gordon W Mclean, Valerie G. Brunton, Neil O Carragher, Egle Avizienyte, Jeff Evans, Margaret C. FrameAbstract:Focal-Adhesion Kinase (FAK) is an important mediator of growth-factor signalling, cell proliferation, cell survival and cell migration. Given that the development of malignancy is often associated with perturbations in these processes, it is not surprising that FAK activity is altered in cancer cells. Mouse models have shown that FAK is involved in tumour formation and progression, and other studies showing that FAK expression is increased in human tumours make FAK a potentially important new therapeutic target.
-
The role of Focal-Adhesion Kinase in cancer — a new therapeutic opportunity
Nature reviews. Cancer, 2005Co-Authors: Gordon W Mclean, Valerie G. Brunton, Neil O Carragher, Egle Avizienyte, Jeff Evans, Margaret C. FrameAbstract:Focal-Adhesion Kinase (FAK) is an important mediator of growth-factor signalling, cell proliferation, cell survival and cell migration. Given that the development of malignancy is often associated with perturbations in these processes, it is not surprising that FAK activity is altered in cancer cells. Mouse models have shown that FAK is involved in tumour formation and progression, and other studies showing that FAK expression is increased in human tumours make FAK a potentially important new therapeutic target.
Egle Avizienyte - One of the best experts on this subject based on the ideXlab platform.
-
the role of Focal Adhesion Kinase in cancer a new therapeutic opportunity
Nature Reviews Cancer, 2005Co-Authors: Gordon W Mclean, Valerie G. Brunton, Neil O Carragher, Egle Avizienyte, Jeff Evans, Margaret C. FrameAbstract:Focal-Adhesion Kinase (FAK) is an important mediator of growth-factor signalling, cell proliferation, cell survival and cell migration. Given that the development of malignancy is often associated with perturbations in these processes, it is not surprising that FAK activity is altered in cancer cells. Mouse models have shown that FAK is involved in tumour formation and progression, and other studies showing that FAK expression is increased in human tumours make FAK a potentially important new therapeutic target.
-
The role of Focal-Adhesion Kinase in cancer — a new therapeutic opportunity
Nature reviews. Cancer, 2005Co-Authors: Gordon W Mclean, Valerie G. Brunton, Neil O Carragher, Egle Avizienyte, Jeff Evans, Margaret C. FrameAbstract:Focal-Adhesion Kinase (FAK) is an important mediator of growth-factor signalling, cell proliferation, cell survival and cell migration. Given that the development of malignancy is often associated with perturbations in these processes, it is not surprising that FAK activity is altered in cancer cells. Mouse models have shown that FAK is involved in tumour formation and progression, and other studies showing that FAK expression is increased in human tumours make FAK a potentially important new therapeutic target.
-
Focal Adhesion Kinase as a potential target in oncology.
Expert opinion on pharmacotherapy, 2003Co-Authors: Gordon W Mclean, Egle Avizienyte, Margaret C. FrameAbstract:Focal Adhesion Kinase (FAK) is a non-receptor tyrosine Kinase that plays a pivotal role in signal transduction at integrin-linked cellular Adhesions, which mediate cell contact with the extracellular matrix. It has been shown to play a role in the survival of anchorage-dependent cells and to be essential for integrin-linked cell migration – processes that are likely to play important roles in the development of malignancies. FAK is upregulated in a wide variety of human epithelial cancers, with expression being closely correlated to invasive potential. Recently, evidence has emerged directly linking FAK expression to tumour development in vivo, raising the possibility that intervention strategies to block FAK function may potentially provide an opportunity for the development of anticancer therapeutics.